4.3 | | HLCS | 'erythroleukemia; ZRSR2 shRNA' vs 'normal' | disease, genotype | RNA-seq of bone marrow from patients with myelodysplastic syndrome |
-4 | | HLCS | 'pancreatic adenocarcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-3.5 | | HLCS | "after autologous stem cell transplantation" vs "before autologous stem cell transplantation" | time | RNA-seq of human multiple myeloma patients myeloid-derived suppressor cells (M-MDSC) |
-3.4 | | HLCS | 'colorectal carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2.8 | | HLCS | 'breast carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2.5 | | HLCS | 'non-small cell lung carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2.4 | | HLCS | 'hepatobiliary carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2.2 | | HLCS | 'resistant to methotrexate' vs 'sensitive to methotrexate' | phenotype | Networking of differentially expressed genes in human MIA PaCa2 pancreatic cancer cells resistant to methotrexate |
-2.1 | | HLCS | 'differentiated; hAKPC-P' vs 're-differentiated; hIPod' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
-2 | | HLCS | 'SAP130 knock-down' vs 'mock' | RNA interference | RNA-seq analysis of vorinostat-resistant HCT116 cells following gene knockdown of potential vorinostat-resistance candidate genes |
-2 | | HLCS | 'differentiated; hAKPC-P' vs 'undifferentiated; hIPod' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
-1.8 | | HLCS | 'glioblastoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-1.7 | | HLCS | 'SARS coronavirus Urbani ΔORF6 mutant' vs 'mock' at '72 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
-1.6 | | HLCS | 'induced pluripotent stem cell' vs 'fibroblast of dermis' in 'Klinefelter's syndrome' | cell type, disease | Klinefelter syndrome derived hiPSCs show similar XCI behavior as female hPSCs |
-1.6 | | HLCS | 'Digoxin; 400 nanomolar' vs 'DMSO' | compound | Expression profiling of Jurkat cells infected with HIV-1 and treated with digoxin or DMSO |
-1.6 | | HLCS | 'SARS coronavirus Urbani' vs 'mock' at '60 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
-1.5 | | HLCS | 'poly(I:C); 25 microgram per milliliter' vs 'none' in 'none; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-1.5 | | HLCS | 'SARS coronavirus Urbani ΔORF6 mutant' vs 'mock' at '60 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
-1.5 | | HLCS | 'cisplatin' at '24 hour' vs 'none' at '0 hour' | compound, time | Transcription profiling by array of human U87 cells treated with cytotoxic anticancer drug cisplatin or a ruthenium-based compound for 6 or 24 hours compared to untreated controls |
-1.5 | | HLCS | 'differentiated; hAKPC-P' vs 'undifferentiated; hAKPC-P' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
-1.5 | | HLCS | 'SARS coronavirus Urbani' vs 'mock' at '54 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
1.5 | | HLCS | 'anti-m6A' vs 'none' | treatment | Transcription profiling by high throughput sequencing in identification of m6A modified sequences in HepG2 cells |
-1.4 | | HLCS | 'KLF17 overexpression' at '24 day' vs 'wild type' at '0 day' | phenotype, time | RNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression |
-1.4 | | HLCS | 'lipopolysaccharide' vs 'none' in 'normal' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
-1.4 | | HLCS | 'SARS coronavirus Urbani ΔORF6 mutant' vs 'mock' at '54 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
-1.4 | | HLCS | 'SARS coronavirus Urbani' vs 'mock' at '72 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
1.3 | | HLCS | 'sulforaphane; prostate carcinoma' at '6 hour' vs 'sulforaphane; normal' at '6 hour' | compound, disease, time | Genome-wide transcriptome analysis of the dietary chemopreventive phytochemical sulforaphane on normal and prostate cancer cells. |
-1.3 | | HLCS | 'RNH1 knockout' vs 'wild type genotype' | genotype | Expression data from Ribonuclease Inhibitor (RI/Rnh1) deficient Human K562 cells |
-1.3 | | HLCS | '24 hour' vs '0 hour' in 'MCF-10A' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
1.3 | | HLCS | 'P-bodies (cytosolic RNP granules)' vs 'pre-sorted fraction' | fraction | RNA-Seq of purified P-bodies from HEK293 cells |
-1.3 | | HLCS | 'lipopolysaccharide' vs 'none' in 'systemic-onset juvenile idiopathic arthritis' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
1.3 | | HLCS | 'non-triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
-1.3 | | HLCS | 'sepsis' vs 'normal' in 'whole blood' | cell type, disease, treatment | Next generation sequencing of human immune cell subsets across diseases |
1.2 | | HLCS | 'Influenza A virus (A/California/07-00001/2009(H1N1))' vs 'none' in 'poly(I:C); 25 microgram per milliliter; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-1.2 | | HLCS | 'SARS coronavirus Urbani' vs 'none' at '72 hour' | infect, time | SCL006,icSARS CoV Urbani or icSARS Bat SRBD (spike receptor binding domain from the wild type strain Urbani to allow for infection of human and non-human primate cells) infections of the 2B4 clonal derivative of Calu-3 cells - Time course |
-1.2 | | HLCS | '10 unit per milliliter; JFHA' vs 'control' | compound | Primary human hepatocytes treated with IL28B and the HCV JFH1 Genotype 2A clone. |
-1.2 | | HLCS | 'PE e/10 adherent culture' vs 'sphere culture' | clinical information | Gene expression profile in adherent cultures compared to sphere cultures from malignant pleural effusions |
-1.2 | | HLCS | 'West Nile Virus protein E domain DIII' at '6 hour' vs 'none' at '0 hour' | stimulus, time | Transcriptome analysis of human brain microvascular endothelial cells response to interactive DIII domain of protein E of WNV and interactive DIII domain of protein E of TBEV using RNA-seq |
1.2 | | HLCS | 'HER2 Positive Breast Carcinoma; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
1.1 | | HLCS | 'induced MCT8 mutation' vs 'wild type genotype' in 'derived neural cell; T3; 100 nanomolar' | cell type, compound, genotype | RNA-seq analysis of MCT8-deficient and healthy control brain microvascular endothelial cells (BMECs) and neural cells |
-1.1 | | HLCS | 'induced pluripotent stem cell' vs 'fibroblast of dermis' in 'normal' | cell type, disease | Klinefelter syndrome derived hiPSCs show similar XCI behavior as female hPSCs |
-1.1 | | HLCS | 'TIGAR knockdown' vs 'wild type' | phenotype | RNA-seq of human cancer cell line OVCA420* following TIGAR knockdown with shRNA |
-1.1 | | HLCS | 'MDAMB231; cocultured with fibroblast Wi38' vs 'MDAMB231; normal' | cell line, growth condition | System-Wide Analysis Reveals a Complex Network of Tumor-Fibroblast Interactions Involved in Tumorigenicity |
-1.1 | | HLCS | 'Apical anaerobic' vs 'Conventional' | growth condition | Caco-2 cells: cultured in conventional vs apical anaerobic conditions |
-1.1 | | HLCS | 'Human betacoronavirus 2c England-Qatar/2012; 24 hour' vs 'mock; 18 hour' | infect, time | Transcription profiling of human bronchial epithelial cell line Calu-3 2B4 infected with Human Coronavirus MERS-CoV-London |
-1.1 | | HLCS | 'SARS coronavirus Urbani' vs 'none' at '60 hour' | infect, time | SCL006,icSARS CoV Urbani or icSARS Bat SRBD (spike receptor binding domain from the wild type strain Urbani to allow for infection of human and non-human primate cells) infections of the 2B4 clonal derivative of Calu-3 cells - Time course |
1.1 | | HLCS | 'interleukin 13; 100 nanogram per milliliter; air-liquid interface (day 14)' vs 'untreated; submerged (day 8)' | compound, growth condition | Genome-wide expression profiling of an in vitro model for studying esophageal epithelial differentiation |
-1.1 | | HLCS | 'SARS coronavirus Urbani' vs 'mock' at '48 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
-1.1 | | HLCS | 'N-hydroxylated PhIP 1000 nanomolar' vs 'DMSO' | compound, dose | Transcription profiling by array of BEAS 2B cells treated with N-hydroxylated PhIP |
1.1 | | HLCS | 'breast carcinoma' vs 'normal' | disease | Transcription and microRNA profiling of three types of breast tumors, benign fibroadenoma and fibroadenomatosis, and malignant breast carcinoma |
-1.1 | | HLCS | 'metformin; 4 millimolar' vs 'none' in 'MDA-MB-468' | cell line, compound | Gene Expression Microarrays data from human breast cancer cell lines MDA-MB-468 and SkBr3 treated for 48h with 1mM and 4mM of Metformin with non-treated control samples |
1.1 | | HLCS | 'uterine leiomyosarcoma' vs 'normal' | disease | Identification of driver genes in uterine leiomyosarcoma: RNA seq |
-1 | | HLCS | 'Listeria monocytogenes EGD-e' vs 'none' | infect | Transcription profiling by high throughput sequencing of LoVo cells infected with Listeria for 24 hr compared to uninfected cells |
1 | | HLCS | 'DMSO; prostate carcinoma' at '6 hour' vs 'DMSO; normal' at '6 hour' | compound, disease, time | Genome-wide transcriptome analysis of the dietary chemopreventive phytochemical sulforaphane on normal and prostate cancer cells. |
1 | | HLCS | '786-0; renal adenocarcinoma; P01' vs '786-0; renal adenocarcinoma; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1 | | HLCS | 'SARS coronavirus Urbani ΔORF6 mutant' vs 'mock' at '48 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
-1 | | HLCS | 'H1N1 swine influenza virus' vs 'none' at '18 hour' | infect, time | SHAE004: SARS-CoV, SARS-dORF6 and SARS-BatSRBD infection of HAE cultures. |
-1 | | HLCS | 'THZ1 (35 nanomolar)' vs 'none' | compound | RNA-seq of IMR-5/75 neuroblastoma cell line treated with JQ1, THZ1 or combination against untreated controls |
-1 | | HLCS | 'kidney transplant; transplant rejection; borderline' vs 'none; normal; none' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
-1 | | HLCS | 'estrogen receptor alpha shRNA' vs 'scrambled shRNA' | RNA interference | RNA-seq of the human breast cancer ERα-suppressed MCF-7(MCF-7/SP10+) cells and of their internal control MCF-7 (MCF-7/C) cells |
1 | | HLCS | 'non primary Sjogren syndrome sicca' vs 'normal' | block, disease | Transcription profiling by array of parotid tissue from Primary Sjögren’s Syndrome and controls |
-1 | | HLCS | 'BRD2 homozygous knockout' vs 'wild type' | phenotype | RNA-seq of human near-haploid cell line HAP1 with CRISPR-edited frameshift mutations |
-1 | | HLCS | '5-Aza-deoxycytidine' vs 'none' in 'A4573' | cell line, compound | Pharmacologic Inhibition of Epigenetic Modification Reveals Targets of Aberrant Promoter Methylation in Ewing Sarcoma |
